Home > Insider Trading > Filing (0000899243-21-002119)

Filing Details

Accession Number:: 0000899243-21-002119
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-14 20:57:25
Reporting Period:: 2021-01-12

Accepted Time:: 2021-01-14 20:57:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1701541	Black Diamond Therapeutics Inc.	BDTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1637054	Brent Hatzis-Schoch	C/O Black Diamond Therapeutics, Inc. One Main Street, 10Th Floor Cambridge MA 02142	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-12	4,078	$3.20	12,478	No	4	M	Direct
Common Stock	Acquisiton	2021-01-12	7,500	$10.86	19,978	No	4	M	Direct
Common Stock	Disposition	2021-01-12	2,048	$29.92	17,930	No	4	S	Direct
Common Stock	Disposition	2021-01-12	1,669	$30.50	16,261	No	4	S	Direct
Common Stock	Disposition	2021-01-12	147	$31.91	16,114	No	4	S	Direct
Common Stock	Disposition	2021-01-12	103	$32.50	16,011	No	4	S	Direct
Common Stock	Disposition	2021-01-12	100	$34.13	15,911	No	4	S	Direct
Common Stock	Disposition	2021-01-12	7,511	$36.00	8,400	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-12	4,078	$0.00	4,078	$3.20
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-12	7,500	$0.00	7,500	$10.86

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
176,786		2029-06-11	No	4	M	Direct
71,251		2029-12-04	No	4	M	Direct

Footnotes

Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.315 to $30.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.335 to $30.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.46 to $32.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.495 to $32.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.95 to $36.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
25% of the shares subject to this option vested and became exercisable on December 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter.